A new study shows Signatera ctDNA testing may identify older patients with ER+/HER2- breast cancer who can manage their care ...

In undertaking this survey, researchers aimed to assess the limitations of ctDNA testing in the clinic, as well as areas in which it is considered clinically meaningful.

Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove ...

New data from two large studies presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GICS) 2025 provide evidence of the clinical utility of circulating tumor DNA (ctDNA) testing in ...

Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal cancer (CRC) most likely to benefit from adjuvant therapy, analyses of two ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...

Please provide your email address to receive an email when new articles are posted on . Approximately 25% of patients had ctDNA- or imaging-confirmed recurrence. More than 30% had evidence of ...

India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...